

Metabolic Abnormalities in Williams-Beuren Syndrome

Palacios-Verdú, María Gabriela^{1,2,3}, Segura-Puimedon, María^{2,3*}, Borralleras, Cristina^{1,2,3}, Flores, Raquel^{1,2,3}, Del Campo, Miguel^{2,3,4}, Campuzano, Victoria^{1,2,3}, Pérez-Jurado, Luis Alberto^{1,2,3}

1. Genetics Unit. Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona 08003, Spain.
2. Hospital del Mar Research Institute (IMIM), Barcelona 08003, Spain.
3. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona 08003, Spain.
4. Programa de Medicina Molecular i Genètica, Hospital Vall d'Hebron, Barcelona, Spain

* Current address: Institut für Integrative und Experimentelle Genomik. Germany · Lübeck

Corresponding author contact information

Dr. Luis Alberto Pérez-Jurado

Genetics Unit. Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Dr. Aiguader 88, Barcelona 08003, Spain

Tel: +34 933 160 856.

E-mail: luis.perez@upf.edu

Word count: Abstract 238, manuscript 3968 (403,762,1508,1289), with 4 Figures, 2 Tables and 50 references. There is also a Supplementary Annex with 5 Figures and 7 Tables.

ABSTRACT

Background: Williams-Beuren syndrome (WBS, OMIM-194050) is a neurodevelopmental disorder with multisystemic manifestations caused by a 1.55–1.83 Mb deletion at 7q11.23 including 26-28 genes. Reported endocrine and metabolic abnormalities include transient hypercalcemia of infancy, subclinical hypothyroidism in ~30% of children, and impaired glucose tolerance in ~75% of adult individuals. The purpose of this study was to further study metabolic alterations in WBS patients, as well as in several mouse models to establish potential candidate genes.

Methods: We analyzed several metabolic parameters in a cohort of 154 WBS individuals (data available from 69-151 cases per parameter) as well as in several mouse models with complete and partial deletions of the orthologous WBS locus, and searched for causative genes and potential modifiers.

Results: Triglyceride plasma levels were significantly decreased in WBS individuals while cholesterol levels were slightly decreased compared to controls. Hyperbilirubinemia, mostly unconjugated, was found in 18.3% of WBS cases and correlated with subclinical hypothyroidism and hypotriglyceridemia suggesting common pathogenic mechanisms. Haploinsufficiency at *MLXIPL* and increased penetrance for hypomorphic alleles at the *UGT1A1* gene promoter might underlie the lipid and bilirubin alterations. Other disturbances included increased protein and iron levels, as well as the known subclinical hypothyroidism and glucose intolerance.

Conclusions: Our results show that several unreported biochemical alterations, related to haploinsufficiency for specific genes at 7q11.23, are relatively common in WBS. The early diagnosis, follow-up and management of these metabolic disturbances could prevent long-term complications in this disorder.

Key words: Williams-Beuren syndrome, WBS murine models, metabolic profile, triglyceride cholesterol, bilirubin.

INTRODUCTION

Williams-Beuren syndrome (WBS, OMIM 194050) is a neurodevelopmental disorder characterized by multisystemic manifestations of variable expressivity, including dysmorphic features, supravalvular aortic stenosis and other vascular stenosis, hyperacusis and intellectual deficit with an uneven neurocognitive profile presenting relative strengths in language and weaknesses in visuospatial construction.¹ It has an incidence of 1/7,500 to 1/20,000 births.^{2,3} WBS is caused by a recurrent 1.55-1.83 Mb heterozygous deletion at chromosome band 7q11.23, which includes 26 to 28 genes.⁴

Several metabolic and endocrine abnormalities have been reported in WBS patients. Transient hypercalcemia has been documented in approximately 15% of infants and children, although further studies are needed to determine its exact prevalence at all ages.⁵ The hypercalcemia is usually mild and may be accompanied by hypercalciuria in some cases.³ A more frequent metabolic abnormality is subclinical hypothyroidism. Studies focused on thyroid function and morphology have shown that approximately 25% of WBS children present a thyroid-stimulating hormone (TSH) elevation and 70% present mild thyroid hypoplasia.^{6,7} Finally, it has been reported that up to 75% of adult WBS individuals develop diabetes or a prediabetic state of impaired glucose tolerance after the administration of a standard oral glucose tolerance test.⁸

Different approaches have provided insight into the contribution of the deleted genes in the WBS critical region to the metabolic phenotype observed in WBS patients.^{2,3} Clinical-molecular correlations in patients with partial deletions suggested that glucose intolerance might be caused by haploinsufficiency at genes of the centromeric half of the deletion interval, the gene coding for MLX-interacting protein-like (*MLXIPL*, OMIM 605678) being the main candidate.⁹ Other genes coding for the general transcription factor Ili (*GTF2I*, OMIM 601679) and the GTF2I repeat domain containing 1 (*GTF2IRD1*, OMIM 604318) could not be ruled out.¹⁰ The metabolic phenotype of single gene knock-out (KO) mouse models also contributed to associate glucose alterations to the *Mlxip1*¹¹ and syntaxin 1a (*Stx1a*, OMIM 186590) genes.¹² Moreover, *Mlxip1* knock-out mice presented reduced lipogenesis and a reduction in adipose tissue.¹¹

We have further studied the metabolic alterations in a cohort of WBS patients as well as in several mouse models to establish potential gene candidates. We have identified novel metabolic alterations including relative hypotriglyceridemia and hyperbilirubinemia in a high proportion of WBS

individuals, and searched for genetic variants that could act as modifiers for the expression of these metabolic phenotypes. The diagnosis and management of these metabolic alterations could help prevent potential long-term complications in these patients.

MATERIALS AND METHODS

Subjects and metabolic data

Biochemical and hormonal parameters were analyzed in a cohort of a 154 WBS individuals with well-characterized 7q11.23 deletions (Supplementary Table S1). Only patients with common recurrent deletions were included in our study; 89% (137/154) had a 1.55 Mb deletion, while 11% (17/154) carried a 1.83 Mb deletion.^{4 13}

The majority of these patients were visited in two large clinical centers in Spain (88/154) and data was also collected from other multiple hospitals in Spain (33/154), Brazil (17/154), Portugal (14/154) and Argentina (2/154). Patients included in the study had a mean age of 12.98 ± 9.03 years (range from 0.2-47 years), 80 males (12.54 ± 9.11 years) and 74 females (13.45 ± 8.98 years). Individuals younger than 18 years old were considered children (n=116), while individuals 18 years of age and older were classified as adults (n=38).

All parameters were measured at the patient's referral medical center, following the procedures established by each laboratory. We used common reference intervals for each parameter to calculate z-score values and determine patients with outlier values. We also analyzed our data by grouping them in percentiles. The reference intervals for most laboratory tests with a normal distribution correspond to the 2.5 and 97.5 percentiles (mean \pm 1.96SD), in which the central 95% of results are obtained from healthy individuals.¹⁴ For most biochemical parameters we used published reference values from the Spanish population.^{15 16} For bilirubin levels we used the reference values of the medical centers from which we had more patients. To detect possible biases related to the different diagnostic laboratories, we compared the z-score values and the indexes obtained by the medical center of origin.

Polymorphism genotyping

Genetic variants previously reported to be associated with triglyceride or total bilirubin concentration were selected. The dinucleotide repeat (TA)₆₋₇ polymorphism in the TATA Box of the

UDP-glycosyltransferase 1 family, polypeptide A1 (*UGT1A1*, OMIM 191740) gene promoter (rs8175347) was studied in 79 WBS patients with bilirubin levels available, as well as in population controls (n=94), as previously reported.¹⁷ We also studied a non-synonymous SNP (rs4149056) in the solute carrier organic anion transporter family, member 1B1 gene (*SLCO1B1*, OMIM 604843) associated with serum bilirubin levels¹⁸, and an intronic SNP (rs799160) at *MLXIPL* associated with triglyceride levels.¹⁹ SNPs were genotyped using the Sequenom MassArray iPLEX system (Sequenom Inc.). Two HapMap samples and a trio were included in the assay for quality control, and no discordant genotypes were found.

For association analyses, we compared the allelic frequencies of extreme phenotypes. In case of triglyceride levels, cases were WBS individuals with values below the 5th percentile and controls were WBS individuals with values above the 50th percentile. Regarding bilirubinemia, cases were WBS individuals with values above the 97.5th percentile and controls were WBS individuals with values below the 25th percentile.

Animal models

The study was performed in accordance with the ARRIVE guidelines for the reporting of *in vivo* experiments (<http://www.nc3rs.org/ARRIVE>). Four groups of mice were used, all bred on a majority C57BL/6J background (97%) (Supplementary Figure S1): complete deletion (CD) mice bearing a heterozygous 1.1 Mb deletion of the orthologous WBS locus from *Gtf2i* to *Fkb6*,²⁰ mice with approximately half deletions of the interval, called the distal deletion (DD) (0.67 Mb from *Limk1* to *Trim50*) and the proximal deletion (PD) (0.45 Mb from *Gtf2i* to *Limk1*),²¹ and the wild-type (WT) littermates as controls. Tail clipping was performed within 4 weeks of birth to obtain DNA using standard protocols and determine the genotype by a Multiple Ligation-dependent Probe Amplification (MLPA) assay (primers²² in Supplementary Table S2).

Metabolic analyses in mice, histological and anthropometric analyses are described in detail in Supplementary Material and Methods.

Candidate-gene expression studies

Liver samples were obtained from 4 mice per genotype at 26±1.1 weeks old. RNA was extracted using TRIZOL reagent (Invitrogen) according to the manufacturer's instructions. cDNA was

prepared from 1µg total RNA using random hexamers and SuperScript II RNase reverse transcriptase (Invitrogen). The expression of *Ugt1a1* and *Rps28* (house-keeping control gene) were evaluated by quantitative real-time PCR (qRT-PCR) with primers spanning exons (Supplementary Table S2) and the Power SYBR Green PCR Master Mix using the 7900 HT Fast Real Time PCR System (Applied Biosystems). Samples were analyzed in triplicates in three independent experiments, and were discarded when the variation coefficient was >20%.

Statistical analyses

Statistical analysis was performed using the package SPSS 19.0 according to the characteristics of each variable. Specifically Chi-squared, T-Student Test, ANOVA with a post hoc DMS comparison between multiple groups and non-parametric tests were used when needed. A p-value <0.05 denoted the presence of statistically significant differences. Bonferroni's correction was performed for the metabolic analyses in mice.

RESULTS

Metabolic disturbances in WBS individuals

Significant differences with respect to the expected values were observed for the following biochemical and hormonal parameters: TSH, glucose, triglyceride, cholesterol, total bilirubin, direct bilirubin, indirect bilirubin, transferrin, and total protein and albumin levels (Tables 1 and S1).

Table 1. Biochemical parameters studied in WBS individuals.

Biochemical Parameter	Total individuals assessed No (%)	Z-Score (Mean±SD)	Percentiles (%)		
			<p2.5	p2.5-97.5	>p97.5
TSH	83/154 (53.9%)	1.158 ± 1.78	0%	68.7%	31.3%
Glucose	151/154 (98.1%)	0.642 ± 2.261	2.0%	90.7%	7.3%
Triglycerides*	115/154 (74.7%)	-0.146 ± 0.887	18.3%*	79.1%	2.6%*
Total Cholesterol*	129/154 (83.8%)	-0.194 ± 0.978	12.4%*	83.7%	3.9%*
Total Bilirubin	89/154 (57.8%)	0.499 ± 2.47	1.1%	78.7%	20.2%
Direct Bilirubin	53/154 (34.4%)	-0.161 ± 1.26	5.7%	86.8%	7.5%
Indirect Bilirubin	53/154 (34.4%)	2.08 ± 5.09	0%	66%	34%

Iron	70/154 (45.5%)	0.715 ± 2.471	7.1%	66.7%	21.4%
Transferrin	69/154 (44.8%)	0.378 ± 0.851	0%	95.7%	4.3%
Total Protein	88/154 (57.1%)	1.13 ± 1.25	0%	72.7%	27.3%
Albumin	73/154 (47.4%)	0.96 ± 0.886	0%	89%	11%

Mean Z-score value, percentage of individuals below the 2.5th percentile, between the 2.5-97.5th percentile and above the 97.5th percentile. *For triglycerides and total cholesterol, percentage of individuals below the 5th percentile, between the 5-95th percentile and above the 95th percentile.

Subclinical hypothyroidism

Subclinical hypothyroidism (defined by mild TSH elevation with normal T3/T4 levels) was present in 31.3% of patients (26/83), with no gender differences. The values followed a bimodal distribution, with a second peak at the 97.5th percentile (Supplementary Figure S2). There were 20 patients with values above 2.5 standard deviations (SD). When compared by age, these patients were significantly younger (9.35 ± 7.22 years) than the rest of the cohort with TSH values available (15.02 ± 9.94 years) ($p = 0.021$). There was a significant correlation between age and TSH values ($r(81) = -0.356$, $p = 0.001$) and z-score value ($r(81) = -0.356$, $p = 0.001$). Increased TSH levels occurred significantly more frequently in children than in adults with WBS (Supplementary Table S3). Three patients with congenital hypothyroidism and one with autoimmune thyroiditis were excluded from the analysis.

Hyperglycemia

Basal glucose plasma levels were increased above the 97.5th percentile in 7.3% of patients (11/151), 9 children (8%) and 2 adults (5.3%) (Table 1). Only one of these patients had a diagnosis of diabetes mellitus type 1. The histogram of glucose percentiles followed a normal distribution, with a small peak at 95 to 97.5th percentiles (Supplementary Figure S3).

Hypotriglyceridemia and lipid profile

Triglyceride plasma levels were decreased in WBS individuals; the values were arranged in a bimodal distribution with a first peak at the 2.5 - 5th percentile and a second at the 25 - 50th percentile (Figure 1.A). Specifically, 18.3% (21/115) of WBS patients had levels below the 5th percentile. There was no relationship with body mass index values, in the overweight or obese range in approximately half of these patients (8/17). Only 2.6% of patients (3/115) had hypertriglyceridemia and two of them presented associated hypothyroidism. The mean z-score value for triglyceride levels in our cohort of

WBS patients was below the reference interval mean (-0.146 ± 0.887) (Table 1). The distribution of the z-score values followed a normal distribution with a shift towards the left (Figure 1.B).




Figure 1. A. Histogram of triglyceride plasma levels in percentiles in WBS individuals. **B.** Histogram of the distribution of triglyceride z-score values.

Cholesterol levels followed a bimodal distribution when analyzed by percentiles or z-score values (Supplementary Figure S4). Only one patient had total cholesterol values above the 97.5th percentile. Cholesterol levels were below the 5th percentile in 12.4% (16/129) patients.

Hyperbilirubinemia

Total bilirubin (TB) levels were increased in 20.2% (18/89) of WBS patients. Two previously described patients with portal hypertension were excluded from the analysis,²³ as well as a patient diagnosed with beta-thalassemia minor. TB levels followed a bimodal distribution, with a second peak at the 97.5th percentile and a median between the 25-50th percentiles (Figure 2). There were 10 individuals with values above 3 SD (z-score range 3.5-15.78), with equal gender distribution. Indirect hyperbilirubinemia was present in 34% (18/53) of WBS individuals and the distribution was also bimodal, while direct bilirubin (DB) levels were only increased in 7.5% (4/53) of WBS cases. There were also 5 individuals with normal TB levels and an increase of either IB or DB alone. Hepatic function parameters (AST, ALT, gGT) were normal in all cases with hyperbilirubinemia but one, who had a slight increase in AST and ALT but normal gGT levels. Out of the 14 individuals with hyperbilirubinemia and fractionated bilirubin levels available, unconjugated hyperbilirubinemia (DB/TB ratio <30%) was present in 28.6% (4/14) while mixed hyperbilirubinemia (DB/TB ratio 30-70%) was

found in the remaining 71.4% (10/14). None presented a conjugated hyperbilirubinemia (DB/TB ratio >70%). Individuals with hyperbilirubinemia were significantly older than those with normal bilirubin levels (20.21 ± 10.31 years versus 11.82 ± 8.40 years, respectively. $p=0.001$). TB and IB levels were more frequently increased in adults compared to children (Table S3).




Figure 2. A. Histogram of total bilirubin plasma levels in percentiles in WBS individuals. **B.** Histogram of total bilirubin z-score values.

Abnormal protein and iron levels

A high proportion of WBS individuals displayed elevated total protein (27.3%) and elevated albumin levels (11%). Only 7 of the 22 cases with hyperproteinemia and albumin levels available had an elevation of this parameter. Total protein levels followed a bimodal distribution with a second peak at 97.5th percentile.

We also found alterations in iron metabolism, with 21.4% (15/70) individuals showing iron concentrations above the 97.5th percentile. Hemoglobin and hematocrit levels were normal in all cases. Iron concentration had a bimodal distribution with a first peak at the 25-50th percentile and a second at >p97.5th percentile. Iron z-score values followed a normal distribution with a shift towards the right.

Correlations between metabolic disturbances

TSH z-score values correlated significantly with total bilirubin z-score values in an inverse manner ($r(66)=-0.328$, $p=0.006$). Triglyceride z-score value correlated significantly with total bilirubin z-score ($r(78)=-0.220$, $p=0.050$) and with total protein z-score value ($r(79)=-0.321$, $p=0.003$) in an inverse manner. Cholesterol z-score values also correlated with direct bilirubin z-score values ($r(51)=-0.436$, $p=0.001$). As expected, total protein z-score values correlated significantly with albumin z-score values ($r(71)=0.666$, $p<0.001$). We did not find any correlation of the biochemical alterations detected and molecular data at 7q11.23, either the size or the parental origin of the deletion.

Genetic modifiers of the lipid and bilirubin disturbances

In order to test whether genetic variants at the non-deleted allele might be responsible for the variation in the lipid profile of WBS individuals, we genotyped a SNP of the *MLXIPL* gene previously associated with hypotriglyceridemia.¹⁹ We compared allelic frequencies of WBS individuals with triglyceride values below the 5th percentile ($n=21$) to those with triglyceride values above the 50th percentile were considered controls ($n=24$). No significant differences were found between cases and controls (Supplementary Table S4).

We also tested whether the hyperbilirubinemia observed in WBS patients was related to known genetic susceptibility factors: a dinucleotide repeat polymorphism at the *UGT1A1* promoter and a SNP at the *SLCO1B1* gene.^{18,24} The *UGT1A1* polymorphism was studied in 79 WBS patients with bilirubin values available and 94 Spanish population controls (no bilirubin levels available). Allelic frequencies were not significantly different in WBS individuals and controls (Supplementary Table S5). *UGT1A1* genotype was significantly associated with elevated plasma concentrations ($>2.5SD$) of TB ($p<0.001$) and IB ($p<0.001$) in WBS (DB ($p=0.055$)). The penetrance of hyperbilirubinemia in WBS individuals homozygous for the *UGT1A1*-promoter allele [(TA)₇] was of 72.7%. Hyperbilirubinemia was present in 13.3% of [(TA)₆/(TA)₇] heterozygous WBS individuals, either unconjugated or mixed hyperbilirubinemia, and 13.2% of [(TA)₆] homozygous WBS individuals, all with unconjugated hyperbilirubinemia (Figure 3). Although there was a significant correlation between *UGT1A1* genotypes and bilirubin levels, specifically increased bilirubin in patients homozygous for [(TA)₇], there was a great variability of bilirubin levels among individuals with the same *UGT1A1* genotype. However, no significant differences in the allelic frequencies of the *SLCO1B1* SNP genotypes were observed in WBS with respect to bilirubin levels.




Figure 3. Total bilirubin (TB), direct bilirubin (DB) and IB z-score values with respect to *UGT1A1* genotype (mean \pm SD). Significant differences were found between genotypes with respect to TB ($F(2,76)=6.412$, $p=0.003$), DB ($F(2,49)=5.497$, $p=0.007$) and IB ($F(2,49)=4.397$, $p=0.018$).

Metabolic disturbances in WBS mouse models

TSH was measured in all mouse models at 25 weeks of age (Table 2). Only PD mice had a significant increase in TSH levels compared to WT ($p=0.004$). Basal blood glucose level at 25 weeks and the intraperitoneal glucose tolerance test (IPGTT) in 11 weeks old mice showed no significant differences between WT animals and deletion mouse models (Figure 4.A). A morphological analysis of the pancreatic Langerhans islets revealed that CD mice had a higher percentage of smaller islets compared to the WT (66% in CD versus 48.8% in WT) and less bigger islets (0.51% in CD versus 6.51% in WT) (Figure 4.B).

Table 2. Metabolic parameters analyzed in WBS mice models at 25 weeks of age.

	WT	CD	DD	PD
Age (weeks)	26.27 \pm 0.8	26.11 \pm 0.6	25.7 \pm 1.25	25.44 \pm 1.74
Triglycerides (mg/dL) (n ^o mice)	99.4 \pm 9.97 (8)	104.1 \pm 21.67 (8)	83.91 \pm 12.41 (7)	84.38 \pm 14.4 (4)
Total Cholesterol (mg/dL) (n ^o mice)	117.1 \pm 28.16 (15)	123.6 \pm 6.61 (7)	131.48 \pm 16.8 (10)	124.6 \pm 18.6 (10)
Total Bilirubin (mg/dL) (n ^o mice)	0.617 \pm 0.343 (13)	0.506 \pm 0.211 (4)	0.45 \pm 0.25 (6)	0.471 \pm 0.221 (6)
Direct Bilirubin (mg/dL) (n ^o mice)	0.419 \pm 0.36 (13)	0.303 \pm 0.15 (4)	0.158 \pm 0.086 (6)	0.202 \pm 0.126 (6)

Indirect Bilirubin (mg/dL) (n° mice)	0.198 ± 0.137 (13)	0.204 ± 0.117 (4)	0.293 ± 0.200 (6)	0.269 ± 0.116 (6)
Total Protein (mg/dL) (n° mice)	4791 ± 314 (14)	4747 ± 422 (12)	4894 ± 333 (10)	5015 ± 161 (12)
Glucose (mg/dL) (n° mice)	173.9 ± 49.9 (12)	167.8 ± 41.1 (8)	189.6 ± 59.9 (8)	157 ± 52.8 (3)
TSH (uIU/mL) (n° mice)	0.142 ± 0.014 (5)	0.116 ± 0.063 (3)	0.193 ± 0.032 (3)	0.223 ± 0.054* (6)

All values are the mean ± SD. Asterisks represent significant differences of at least $p < 0.006$ (after Bonferroni's correction) compared to wild type (WT) mice.




Figure 4. A. Intrapерitoneal glucose tolerance test. Results represent the mean ± SD (n = 8 - 16). **B.** Langerhans islets area analysis. Results represent the mean ± SD (n = 3 - 6).

Triglyceride plasma concentration was significantly decreased only in the DD and PD mice at 4.5 weeks of age when compared to the WT ($p=0.003$ & $p=0.005$, respectively), a decrement that was milder and non-significant at 26 weeks of age (Table 2). Total cholesterol, high-density lipoprotein and low-density lipoprotein levels were not significantly different in any group of animals at any age (Tables 2 & S6).

An anthropometric analysis was done at 25 weeks in mice; whole body, liver, perirenal and gonadal fat weight were recorded (Supplementary Table S7). PD mice had significantly increases in total body weight ($p=0.018$), liver weight with respect to total body weight ($p=0.002$) and total fat ($p=0.015$) when compared to WT.

Total protein levels were measured in mice at 25 weeks (Table 2). PD mice had increased concentration when compared to WT, although it did not reach statistical significance after Bonferroni's correction.

Bilirubin levels were also studied at 4.5 and 25 weeks in mice with no significant differences in absolute values between groups of animals. WT mice had almost the same TB values at both time points, although a relative increase of DB and decrease of IB was observed at 25 weeks resulting in increased DB to TB ratio (DB/TB) ($41.9\pm 12.1\%$ versus $61.2\pm 22.3\%$). In the case of DD mice, TB decreased at 25 weeks maintaining a similar DB/TB ratio at both time points ($31.7\pm 10.8\%$ versus $38.4\pm 16.6\%$). For PD mice, all values increased at 25 weeks except the DB/TB ratio that was similar at both time points ($44.2\pm 14.3\%$ versus $41.9\pm 12.1\%$).

In order to test for a putative differential compensatory regulation of the *Ugt1a1* gene in the different mice, we measured its relative expression in RNA isolated from mice liver by qRT-PCR. No differences were found with respect to *Ugt1a1* expression levels between the four mouse genotypes studied (Supplementary Figure S5).

DISCUSSION

We describe several unreported biochemical alterations relatively frequent in WBS children and adults, such as hypotriglyceridemia, increased bilirubin levels and increased total protein and albumin levels, and we document the previously described subclinical hypothyroidism and glucose intolerance.

Subclinical hypothyroidism has been previously reported in WBS with a frequency ranging from 15 to 31.5%^{7 25 26}. In our cohort, 31.3% of WBS individuals presented subclinical hypothyroidism. Patients presenting this alteration were significantly younger than patients with normal TSH plasma concentrations. A suggested mechanism for its highly prevalence in WBS is the immaturity of the hypothalamic-pituitary-thyroid axis that may associate some degree of thyroid hypoplasia and spontaneously resolves at increasing age.²⁶ Anti-thyroid autoimmunity is rarely seen, just a single

case in our cohort. Thus, hormonal replacement therapy is not usually required and should be reserved for patients with worsening thyroid function.²⁵ The finding of elevated TSH values only in mice with deletion of the PD interval suggest that haploinsufficiency for one or more genes located in this interval could contribute to this developmental phenotype of the thyroid axis.

Impaired glucose tolerance has been reported in 75% of WBS adult individuals.⁸ We found slight basal hyperglycemia in 7,3% of the WBS individuals, and a single case with diabetes mellitus type I. Considering the young mean age of these patients with basal hyperglycemia in our cohort (10,2 ±8,9 years), the findings are quite relevant and further support the recommendation for an oral glucose tolerance test in WBS individuals in the second or third decade of life, in order to detect and treat this disturbance.⁸ Neither hyperglycemia nor glucose intolerance was seen in the three WBS mouse models studied at 11 weeks of age. However, morphologic alterations in pancreatic Langerhans islets were observed in CD mice, with a significant reduction in the islets size. A similar morphologic alteration, with smaller islet area and losses of beta and alpha cells, has been reported in type 2 diabetes patients.²⁷ The reduction of islet size may not have a clinical repercussion at a young age but may predispose to dysfunction in adulthood. Long-term functional consequences, insulin and glucose levels, should be studied in older animals.

Triglyceride levels were below the 5th percentile in 18% of WBS individuals in our cohort, with a global distribution shifted towards the left. However, none of them presented extremely low triglyceride values below 2.5 SD. Total cholesterol was also distributed in a bimodal curve with only one patient presenting values above the 97.5th percentile, in contrast with the high prevalence of hypercholesterolemia in the adult and pediatric Spanish population.^{28 29} Therefore, the most common lipid profile in WBS is hypotriglyceridemia with low-normocholesterolemia, which is associated with low risk for cardiovascular disease. Nevertheless, given the high prevalence of other cardiovascular risk factors, including cardiac and vascular stenoses, hypertension and glucose intolerance, all WBS individuals should have periodic evaluations of the lipid profile to intervene if necessary.

An excellent candidate gene for the lipid profile in WBS is *MLXIPL*, invariably deleted in patients. *MLXIPL* encodes a basic-helix-loop-helix leucine zipper transcription factor of the Myc/Max/Mad superfamily^{30 31} that preferentially regulates triglyceride synthesis and storage.^{32 33} Several SNPs at or near *MLXIPL* have been associated with high and low triglyceride plasma concentration in different populations.^{19 34–36} However, we ruled out any association of the variable

expression of hypotriglyceridemia in WBS patients with a common SNP in the non-deleted copy of *MLXIPL*. Homozygous mice knock-out for *Mlxipl* present decreased lipogenesis, low plasma free fatty acids and reduced adipose tissue mass, although heterozygous mice were not studied.¹¹ We observed significantly decreased triglyceride levels at 4.5 weeks of age in two of the mouse models analyzed harboring non-overlapping deletions, DD and PD. Unfortunately CD mice were not studied at this time point due to the unavailability of enough sample.³⁷ At 26 weeks of age, hypotriglyceridemia only persisted in DD mice, hemizygous for *Mlxipl*. Therefore, the major cause for hypotriglyceridemia in WBS and mouse models is, most likely, haploinsufficiency at *MLXIPL*, although the more penetrant phenotype at early ages could be modified by other genes of the interval, as well as by environmental factors such as diet.¹¹

The somehow inconsistent findings of some biochemical phenotypes in partial deletion mice absent in the complete deletion mice are relatively common in mouse models of segmental or complete aneuploidy. When phenotypes of microdeletions are the result of interactive effects of the haploinsufficient genes, there may be compensatory effects with partial deletions absent in full deletions^{20 38 39}. In addition, the fail to show relevant phenotypes in mouse models with similar genotypes to human underscores the physiological differences between mouse and human. Therefore, a simple explanation of how haploinsufficiency of some deleted genes causes the phenotype is neither adequate nor possible with the current data.

Mildly elevated total bilirubin levels were observed in a relatively high proportion of WBS individuals (20.2%). Hyperbilirubinemia may indicate increased degradation of hemoglobin (hemolytic disease), reduced transport of bilirubin into the liver, reduced glucuronidation of bilirubin or hepatobiliary disease. In the absence of hemolysis or underlying liver disease, the mild mostly unconjugated hyperbilirubinemia of WBS individuals is consistent with an additional diagnosis of Gilbert syndrome (OMIM 143500). Gilbert syndrome, characterized by intermittent mild jaundice, has a prevalence in the range of 6-8%.^{24 40-43} It is mainly caused by a hypomorphic allele at the promoter of the *UGT1A1* gene, encoding a glucuronosyltransferase enzyme responsible for the glucuronidation essential for bilirubin excretion.^{18 24 44} The penetrance is incomplete and varies depending on the criteria used to define the phenotype, being around 40% for the homozygous hypomorphic allele. Genotype frequencies at *UGT1A1* in our WBS cohort were similar to those reported in the Spanish population⁴⁵, and bilirubin levels correlated with *UGT1A1* genotype, as previously reported.^{24 46 47} No association

was found with *SLCO1B1*,¹⁸ coding for an hepatic transporter in the basolateral membrane of hepatocytes for bilirubin.^{18 48} Therefore, the increased frequency of unconjugated hyperbilirubinemia or Gilbert syndrome in WBS, three fold that of the general population, is partly due to increased penetrance of homozygous *UGT1A1* hypomorphic alleles (72.7%). However, 13.2% of WBS patients homozygous for the functional allele also had hyperbilirubinemia, and normal bilirubin levels and normal expression of *Ugt1a1* in hepatic tissue was found in all mouse models tested, implying that *UGT1A1* is not the only cause of hyperbilirubinemia in WBS patients. We found that TB z-score values were inversely related with triglyceride z-score values, suggesting common pathogenic mechanisms for the lipid and bilirubin alterations, as described by other studies.^{49 50}

Additional abnormalities were found in our cohort of WBS patients, including elevated total protein in 27.3%, elevated albumin levels in 11%, relatively increased transferrin and elevated iron in 21.4% of WBS patients. As for the other metabolic parameters, a limitation of our study is the relatively small sample size, common when studying endophenotypes in rare diseases. Further studies are needed to confirm these data and better explain the mechanisms underlying the high frequency of these metabolic alterations.

Our data indicate that several unreported biochemical alterations are relatively common in WBS and should be studied in greater detail in order to better define clinical guidelines and prevent potential long-term complications, such as the known consequences of clinical hypothyroidism or diabetes.. The most common metabolic profile observed in WBS, with hypotrygliceridemia and low-normal cholesterol, is indeed associated with an a priori low risk for cardiovascular disease. Given the high cardiovascular risk of these patients due to the developmental and functional anomalies of the elastin deficiency, this metabolic profile could somehow provide a compensatory mechanism. Awareness about this metabolic profile of WBS is relevant to avoid unnecessary studies and interventions, as well as to better identify relevant changes that could have a negative impact on the potential cardiovascular complications.

ACKNOWLEDGEMENTS

We would like to thank all the patients and their families for their consent and support, as well as the physicians who have contributed with the clinical information of their patients, especially Drs. P. Lapunzina, E. Gabau, J. Rosell, E. Guillen, A. González-Meneses, E. del Castillo, J.C. Cabrera, M.

Martínez, R. Duque, F. Ruiz-Cabello, M. Barbosa, G. Mercado and C. Ae Kim. SNP genotyping was performed at the Santiago de Compostela node of the Spanish National Genotyping Centre (www.cegen.org). This work was supported by grants from the Spanish Fondo de Investigación Sanitaria (FIS PI1002512 and PI1302841 to LAP-J), the Catalan Government (SGR2009-1274, SGR2014-1468 and ICREA Acadèmia to LAP-J), the Spanish Ministry of Science and Innovation (SAF2012-40036 to VC), an intramural CIBERER grant (to VC), and AGAUR predoctoral fellowships (FI_B2 00137 to MGP-V and FI_B1 00018 to CB).

COMPETING INTERESTS

Luis A. Pérez-Jurado is scientific advisor of qGenomics, a privately held company that provides genomics services to the scientific and medical community.

REFERENCES

- 1 Mervis CB, Morris CA, Bertrand J, Robinson BF. Williams syndrome: Findings from an integrated program of research. In: Tager-Flusberg H, ed. *Neurodevelopmental Disorders: Contributions to a new framework from the cognitive neurosciences*. Cambridge, MA: : The MIT Press 1999. 65–110.
- 2 Strømme P, Bjørnstad PG, Ramstad K. Prevalence estimation of Williams syndrome. *J Child Neurol* 2002;**17**:269–71.
- 3 Pober BR. Williams-Beuren syndrome. *N Engl J Med* 2010;**362**:239–52.
- 4 Pérez Jurado AL. Williams-Beuren syndrome: a model of recurrent genomic mutation. *Horm Res* 2003;**59 Suppl 1**:106–13.
- 5 Pober BR, Morris CA. Diagnosis and management of medical problems in adults with Williams-Beuren syndrome. *Am J Med Genet C Semin Med Genet* 2007;**145C**:280–90.
- 6 Selicorni A, Fratoni A, Pavesi MA, Bottigelli M, Arnaboldi E, Milani D. Thyroid anomalies in Williams syndrome: investigation of 95 patients. *Am J Med Genet A* 2006;**140**:1098–101.
- 7 Stagi S, Bindi G, Neri AS, Lapi E, Losi S, Jenuso R, Salti R, Chiarelli F. Thyroid function and morphology in patients affected by Williams syndrome. *Clin Endocrinol (Oxf)* 2005;**63**:456–60.
- 8 Pober BR, Wang E, Caprio S, Petersen KF, Brandt C, Stanley T, Osborne LR, Dzuria J, Gulanski B. High prevalence of diabetes and pre-diabetes in adults with Williams syndrome. *Am J Med Genet C Semin Med Genet* 2010;**154C**:291–8.
- 9 Antonell A, Del Campo M, Magano LF, Kaufmann L, de la Iglesia JM, Gallastegui F, Flores R, Schweigmann U, Fauth C, Kotzot D, Pérez-Jurado LA. Partial 7q11.23 deletions further implicate GTF2I and GTF2IRD1 as the main genes responsible for the Williams-Beuren syndrome neurocognitive profile. *J Med Genet* 2010;**47**:312–20.
- 10 Antonell A, Vilardell M, Pérez Jurado LA. Transcriptome profile in Williams-Beuren syndrome lymphoblast cells reveals gene pathways implicated in glucose intolerance and visuospatial construction deficits. *Hum Genet* 2010;**128**:27–37.
- 11 Iizuka K, Bruick RK, Liang G, Horton JD, Uyeda K. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. *Proc Natl Acad Sci U S A* 2004;**101**:7281–6.
- 12 Ohara-Imaizumi M, Fujiwara T, Nakamichi Y, Okamura T, Akimoto Y, Kawai J, Matsushima S, Kawakami H, Watanabe T, Akagawa K, Nagamatsu S. Imaging analysis reveals mechanistic differences between first- and second-phase insulin exocytosis. *J Cell Biol* 2007;**177**:695–705.
- 13 Bayés M, Magano LF, Rivera N, Flores R, Pérez Jurado LA. Mutational mechanisms of Williams-Beuren syndrome deletions. *Am J Hum Genet* 2003;**73**:131–51.
- 14 Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. *Clin Chem* 2000;**46**:2027–49.
- 15 Ángel Mejía G, Angel Ramelli M. *Interpretación Clínica del Laboratorio*. 7ma Edició. Madrid: : Médica Panamericana 2006.

- 16 Gómez-Gerique JA, Gutiérrez-Fuentes JA, Montoya MT, Porres A, Rueda A, Avellaneda A, Rubio MA. [Lipid profile of the Spanish population: the DRECE (diet and risk of cardiovascular disease in Spain) study. DRECE study group]. *Med Clin (Barc)* 1999;**113**:730–5.
- 17 Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. *Lancet* 1996;**347**:578–81.
- 18 Johnson AD, Kavousi M, Smith A V, Chen M-H, Dehghan A, Aspelund T, Lin J-P, van Duijn CM, Harris TB, Cupples LA, Uitterlinden AG, Launer L, Hofman A, Rivadeneira F, Stricker B, Yang Q, O'Donnell CJ, Gudnason V, Witteman JC. Genome-wide association meta-analysis for total serum bilirubin levels. *Hum Mol Genet* 2009;**18**:2700–10.
- 19 Kooner JS, Chambers JC, Aguilar-Salinas C a, Hinds D a, Hyde CL, Warnes GR, Gómez Pérez FJ, Frazer K a, Elliott P, Scott J, Milos PM, Cox DR, Thompson JF. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. *Nat Genet* 2008;**40**:149–51.
- 20 Segura-Puimedon M, Sahún I, Velot E, Dubus P, Borralleras C, Rodrigues AJ, Valero MC, Valverde O, Sousa N, Herault Y, Dierssen M, Pérez-Jurado LA, Campuzano V. Heterozygous deletion of the Williams-Beuren syndrome critical interval in mice recapitulates most features of the human disorder. *Hum Mol Genet* Published Online First: 15 July 2014. doi:10.1093/hmg/ddu368
- 21 Li HH, Roy M, Kuscuoglu U, Spencer CM, Halm B, Harrison KC, Bayle JH, Splendore A, Ding F, Meltzer LA, Wright E, Paylor R, Deisseroth K, Francke U. Induced chromosome deletions cause hypersociability and other features of Williams-Beuren syndrome in mice. *EMBO Mol Med* 2009;**1**:50–65.
- 22 Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. *Methods Mol Biol* 2000;**132**:365–86.
- 23 Del Campo Casanelles M, Gil-Fernández JJ, Casero LFM, Bengoechea MG, Serrano R, Rañada JMF, Jurado LAP. Portal hypertension in Williams syndrome: report of two patients. *Am J Med Genet A* 2003;**118A**:372–6.
- 24 Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. *N Engl J Med* 1995;**333**:1171–5.
- 25 Cherniske EM, Carpenter TO, Klaiman C, Young E, Bregman J, Insogna K, Schultz RT, Pober BR. Multisystem study of 20 older adults with Williams syndrome. *Am J Med Genet A* 2004;**131**:255–64.
- 26 Cambiaso P, Orazi C, Digilio MC, Loche S, Capolino R, Tozzi A, Faedda A, Cappa M. Thyroid morphology and subclinical hypothyroidism in children and adolescents with Williams syndrome. *J Pediatr* 2007;**150**:62–5.
- 27 Kilimnik G, Zhao B, Jo J, Perival V, Witkowski P, Misawa R, Hara M. Altered islet composition and disproportionate loss of large islets in patients with type 2 diabetes. *PLoS One* 2011;**6**:e27445.
- 28 Guallar-Castillón P, Gil-Montero M, León-Muñoz LM, Graciani A, Bayán-Bravo A, Taboada JM, Banegas JR, Rodríguez-Artalejo F. Magnitude and management of hypercholesterolemia in the adult population of Spain, 2008-2010: The ENRICA Study. *Rev Esp Cardiol (Engl Ed)* 2012;**65**:551–8.

- 29 Medrano MJ, Cerrato E, Boix R, Delgado-Rodríguez M. [Cardiovascular risk factors in Spanish population: metaanalysis of cross-sectional studies]. *Med Clin (Barc)* 2005;**124**:606–12.
- 30 De Luis O, Valero MC, Jurado LA. WBSR14, a putative transcription factor gene deleted in Williams-Beuren syndrome: complete characterisation of the human gene and the mouse ortholog. *Eur J Hum Genet* 2000;**8**:215–22.
- 31 Cairo S, Merla G, Urbinati F, Ballabio A, Reymond A. WBSR14, a gene mapping to the Williams-Beuren syndrome deleted region, is a new member of the Mlx transcription factor network. *Hum Mol Genet* 2001;**10**:617–27.
- 32 Dentin R, Benhamed F, Hainault I, Fauveau V, Fougelle F, Dyck JRB, Girard J, Postic C. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. *Diabetes* 2006;**55**:2159–70.
- 33 Iizuka K, Horikawa Y. ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome. *Endocr J* 2008;**55**:617–24.
- 34 Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken M a, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen W-M, Li Y, Scott LJ, Scheet P a, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor D a, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. *Nat Genet* 2008;**40**:161–9.
- 35 Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, Penninx BWJH, Janssens a CJW, Wilson JF, Spector T, Martin NG, Pedersen NL, Kyvik KO, Kaprio J, Hofman A, Freimer NB, Jarvelin M-R, Gyllenstein U, Campbell H, Rudan I, Johansson A, Marroni F, Hayward C, Vitart V, Jonasson I, Pattaro C, Wright A, Hastie N, Pichler I, Hicks A a, Falchi M, Willemsen G, Hottenga J-J, de Geus EJC, Montgomery GW, Whitfield J, Magnusson P, Saarinen J, Perola M, Silander K, Isaacs A, Sijbrands EJG, Uitterlinden AG, Witteman JCM, Oostra B a, Elliott P, Ruokonen A, Sabatti C, Gieger C, Meitinger T, Kronenberg F, Döring A, Wichmann H-E, Smit JH, McCarthy MI, van Duijn CM, Peltonen L. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. *Nat Genet* 2009;**41**:47–55.
- 36 Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T, Voight BF, Bonnycastle LL, Jackson AU, Crawford G, Surti A, Guiducci C, Burt NP, Parish S, Clarke R, Zelenika D, Kubalanza K a, Morken M a, Scott LJ, Stringham HM, Galan P, Swift AJ, Kuusisto J, Bergman RN, Sundvall J, Laakso M, Ferrucci L, Scheet P, Sanna S, Uda M, Yang Q, Lunetta KL, Dupuis J, de Bakker PIW, O'Donnell CJ, Chambers JC, Kooper JS, Hercberg S, Meneton P, Lakatta EG, Scuteri A, Schlessinger D, Tuomilehto J, Collins FS, Groop L, Altshuler D, Collins R, Lathrop GM, Melander O, Salomaa V, Peltonen L, Orho-Melander M, Ordoas JM, Boehnke M, Abecasis GR, Mohlke KL, Cupples LA. Common variants at 30 loci contribute to polygenic dyslipidemia. *Nat Genet* 2009;**41**:56–65.
- 37 Hoff J. Methods of Blood Collection in the Mouse. *Lab Anim* 2000;**29**:47–53.
- 38 Campuzano V, Segura-Puimedon M, Terrado V, Sánchez-Rodríguez C, Coustets M, Menacho-Márquez M, Nevado J, Bustelo XR, Francke U, Pérez-Jurado L a. Reduction of NADPH-oxidase activity ameliorates the cardiovascular phenotype in a mouse model of Williams-Beuren Syndrome. *PLoS Genet* 2012;**8**:e1002458.
- 39 Philip N, Bassett A. Cognitive, behavioural and psychiatric phenotype in 22q11.2 deletion syndrome. *Behav Genet* 2011;**41**:403–12.

- 40 Skierka JM, Kotzer KE, Lagerstedt S a, O’Kane DJ, Baudhuin LM. UGT1A1 genetic analysis as a diagnostic aid for individuals with unconjugated hyperbilirubinemia. *J Pediatr* 2013;**162**:1146–52.
- 41 Owens D, Evans J. Population studies on Gilbert’s syndrome. *J Med Genet* 1975;**12**:152–6.
- 42 Rodrigues C, Vieira E, Santos R, de Carvalho J, Santos-Silva A, Costa E, Bronze-da-Rocha E. Impact of UGT1A1 gene variants on total bilirubin levels in Gilbert syndrome patients and in healthy subjects. *Blood Cells, Mol Dis* 2012;**48**:166–72.
- 43 Clementi M, Di Gianantonio E, Fabris L, Forabosco P, Strazzabosco M, Tenconi R, Okolicsanyi L. Inheritance of hyperbilirubinemia: evidence for a major autosomal recessive gene. *Dig Liver Dis* 2007;**39**:351–5.
- 44 Lin J-P, Cupples LA, Wilson PWF, Heard-Costa N, O’Donnell CJ. Evidence for a gene influencing serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham study. *Am J Hum Genet* 2003;**72**:1029–34.
- 45 Fernández Salazar JM, Remacha Sevilla A, del Río Conde E, Baiget Bastús M. [Distribution of the A(TA)7TAA genotype associated with Gilbert syndrome in the Spanish population]. *Med Clin (Barc)* 2000;**115**:540–1.
- 46 Borucki K, Weikert C, Fisher E, Jakubiczka S, Luley C, Westphal S, Dierkes J. Haplotypes in the UGT1A1 gene and their role as genetic determinants of bilirubin concentration in healthy German volunteers. *Clin Biochem* 2009;**42**:1635–41.
- 47 Kringen MK, Piehler AP, Grimholt RM, Opdal MS, Haug KBF, Urdal P. Serum bilirubin concentration in healthy adult North-Europeans is strictly controlled by the UGT1A1 TA-repeat variants. *PLoS One* 2014;**9**:e90248.
- 48 Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. *Biochem Biophys Res Commun* 2000;**273**:251–60.
- 49 Boon A-C, Hawkins CL, Bisht K, Coombes JS, Bakrania B, Wagner K-H, Bulmer AC. Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome. *Free Radic Biol Med* 2012;**52**:2120–7.
- 50 McArdle PF, Whitcomb BW, Tanner K, Mitchell BD, Shuldiner AR, Parsa A. Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inference. *BMC Cardiovasc Disord* 2012;**12**:16.